KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed EBIT Margin for 8 consecutive years, with 17.82% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 5348.0% to 17.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20.62% through Dec 2025, up 7021.0% year-over-year, with the annual reading at 20.62% for FY2025, 7021.0% up from the prior year.
  • EBIT Margin hit 17.82% in Q4 2025 for Adaptive Biotechnologies, down from 10.95% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 10.95% in Q3 2025 to a low of 621.01% in Q2 2023.
  • Historically, EBIT Margin has averaged 126.36% across 5 years, with a median of 113.0% in 2024.
  • Biggest five-year swings in EBIT Margin: tumbled -50076bps in 2023 and later soared 51146bps in 2024.
  • Year by year, EBIT Margin stood at 162.39% in 2021, then skyrocketed by 56bps to 70.99% in 2022, then tumbled by -119bps to 155.22% in 2023, then surged by 54bps to 71.3% in 2024, then soared by 75bps to 17.82% in 2025.
  • Business Quant data shows EBIT Margin for ADPT at 17.82% in Q4 2025, 10.95% in Q3 2025, and 42.52% in Q2 2025.